PACIFIC BIOSCIENCES OF CALIF (PACB) Forecast, Price Target & Analyst Ratings

NASDAQ:PACB • US69404D1081

Current stock price

1.58 USD
-0.01 (-0.63%)
At close:
1.5898 USD
+0.01 (+0.62%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PACIFIC BIOSCIENCES OF CALIF (PACB).

Forecast Snapshot

Consensus Price Target

Price Target
$2.30
+ 45.25% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$0.14
Revenue Estimate
40.786M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
75.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$2.30
Upside
+ 45.25%
From current price of $1.58 to mean target of $2.30, Based on 16 analyst forecasts
Low
$1.01
Median
$2.55
High
$3.15

Price Target Revisions

1 Month
-7.35%
3 Months
-2.70%

Price Target Summary

16 Wall Street analysts provided a forecast for the next 12 months for PACB. The average price target is 2.3 USD. This implies a price increase of 45.25% is expected in the next year compared to the current price of 1.58.
The average price target has been revised downward by 2.7% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

PACB Current Analyst RatingPACB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

PACB Historical Analyst RatingsPACB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
75.00%
PACB was analyzed by 16 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about PACB.
In the previous month the buy percentage consensus was at a similar level.
PACB was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-14BarclaysMaintains Underweight -> Underweight
2026-03-06BarclaysDowngrade Equal-Weight -> Underweight
2025-12-15BarclaysMaintains Equal-Weight -> Equal-Weight
2025-11-11Piper SandlerMaintains Neutral -> Neutral
2025-11-10Stephens & Co.Maintains Overweight -> Overweight
2025-08-11Piper SandlerMaintains Neutral -> Neutral
2025-06-25BarclaysMaintains Equal-Weight -> Equal-Weight
2025-05-15Stephens & Co.Reiterate Overweight -> Overweight
2025-05-15Piper SandlerMaintains Neutral -> Neutral
2025-04-10Canaccord GenuityMaintains Buy -> Buy
2025-03-25ScotiaBankMaintains Sector Outperform -> Sector Outperform
2025-02-20Piper SandlerReiterate Neutral -> Neutral
2025-02-18Stephens & Co.Reiterate Overweight -> Overweight
2025-02-18Goldman SachsMaintains Neutral -> Neutral
2025-02-14Stephens & Co.Reiterate Overweight -> Overweight
2025-01-23Goldman SachsMaintains Neutral -> Neutral
2024-11-11ScotiaBankMaintains Sector Outperform -> Sector Outperform
2024-11-11UBSDowngrade Buy -> Neutral
2024-11-11Piper SandlerMaintains Neutral -> Neutral
2024-08-28ScotiaBankMaintains Sector Outperform -> Sector Outperform
2024-08-12Morgan StanleyMaintains Equal-Weight -> Equal-Weight
2024-08-08Cantor FitzgeraldReiterate Overweight -> Overweight
2024-08-08Canaccord GenuityMaintains Buy -> Buy
2024-06-03JefferiesInitiate Buy
2024-05-15Morgan StanleyMaintains Equal-Weight -> Equal-Weight

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$0.14
Revenue Estimate
40.786M
Revenue Q2Q
9.78%
EPS Q2Q
90.45%
Number of Analysts
10

Next Earnings Revisions

Revenue (1 Month)
0.08%
Revenue (3 Months)
-3.08%
EPS (1 Month)
-1.60%
EPS (3 Months)
2.53%

Next Earnings Summary

PACB is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.14 USD and the consensus revenue estimate is 40.79M USD.
The next earnings revenue estimate has been revised downward by 3.08% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2032

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
PACB revenue by date.PACB revenue by date.
200.521M
56.29%		154.014M
-23.19%		160.005M
3.89%		178.11M
11.32%		199.74M
12.14%		226.83M
13.56%		255M
12.42%		285.5M
11.96%		373.63M
30.87%		644.64M
72.53%
EBITDA
YoY % growth
PACB ebitda by date.PACB ebitda by date.
-302.265M
-3.12%		-226.829M
24.96%		215.952M
195.20%		-124.644M
-157.72%		-76.466M
38.65%		-79.05M
-3.38%		N/AN/AN/AN/A
EBIT
YoY % growth
PACB ebit by date.PACB ebit by date.
-321.989M
-6.09%		-268.015M
16.76%		-166.483M
37.88%		-165.306M
0.71%		-156.282M
5.46%		-128.79M
17.59%		-128.52M
0.21%		-113.22M
11.90%		-71.298M
37.03%		48.348M
167.81%
Operating Margin
PACB operating margin by date.PACB operating margin by date.
-160.58%-174.02%-104.05%-92.81%-78.24%-56.78%-50.40%-39.66%-19.08%7.50%
EPS
YoY % growth
PACB eps by date.PACB eps by date.
-1.21
13.57%		-1.64
-35.54%		-1.83
-11.59%		-0.52
71.72%		-0.42
18.47%		-0.37
12.61%		-0.34
7.78%		-0.31
9.99%		-0.13
56.67%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-0.14
90.45%		-0.13
8.56%		-0.13
1.92%		-0.13
-9.51%		-0.12
13.08%		-0.11
13.31%		-0.11
15.84%		-0.11
14.62%		-0.09
23.21%		-0.09
17.28%		-0.07
33.46%		-0.06
45.45%
Revenue
Q2Q % growth		40.786M
9.78%		43.678M
9.84%		44.743M
16.39%		48.415M
8.44%		46.711M
14.53%		49.084M
12.38%		50.533M
12.94%		53.988M
11.51%		56.722M
21.43%		59.685M
21.60%		61.113M
20.94%		67.193M
24.46%
EBITDA
Q2Q % growth		-31.467M
-109.67%		-27.183M
-108.21%		-26.622M
-107.38%		-26.112M
-107.95%		-9.18M
70.83%		-11.526M
57.60%		-12.342M
53.64%		-16.524M
36.72%		-24.878M
-171.00%		-26.03M
-125.84%		-20.573M
-66.69%		-16.147M
2.28%
EBIT
Q2Q % growth		-46.367M
-0.87%		-40.355M
8.34%		-39.288M
-117.04%		-42.536M
21.21%		-42.045M
9.32%		-37.976M
5.89%		-36.93M
6.00%		-40.514M
4.75%		-26.948M
35.91%		-28.111M
25.98%		-22.644M
38.68%		-18.248M
54.96%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

PACB Yearly Revenue VS EstimatesPACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
PACB Yearly EPS VS EstimatesPACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -0.5 -1 -1.5

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
21.61%
EPS Next 5 Year
12.88%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
12.07%
Revenue Next 5 Year
12.12%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
22.11%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

PACIFIC BIOSCIENCES OF CALIF / PACB Forecast FAQ

What is the average price target for PACIFIC BIOSCIENCES OF CALIF (PACB) stock?

16 analysts have analysed PACB and the average price target is 2.3 USD. This implies a price increase of 45.25% is expected in the next year compared to the current price of 1.58.

When does PACIFIC BIOSCIENCES OF CALIF (PACB) report earnings?

PACIFIC BIOSCIENCES OF CALIF (PACB) will report earnings on 2026-05-07, after the market close.

What are the consensus estimates for PACB stock next earnings?

The consensus EPS estimate for the next earnings of PACIFIC BIOSCIENCES OF CALIF (PACB) is -0.14 USD and the consensus revenue estimate is 40.79M USD.

What is the consensus rating for PACIFIC BIOSCIENCES OF CALIF (PACB) stock?

The consensus rating for PACIFIC BIOSCIENCES OF CALIF (PACB) is 75 / 100 . This indicates that analysts generally have a positive outlook on the stock.